CRISPR Therapeutics Has $2.4 Billion in Cash and an Approved Drug. Why Is Its Stock Trading Nearly 40% Below the Wall Street Consensus?
Key takeaways
- CRSP NVDA INTC By all accounts, CRISPR Therapeutics (NASDAQ: CRSP) shares should be soaring.
- Initial interest in its sole approved treatment is solid, too.
- Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need.
CRSP NVDA INTC By all accounts, CRISPR Therapeutics (NASDAQ: CRSP) shares should be soaring. The company shares rights to one of the healthcare industry s very few approved gene-editing therapies, and has several more in the works.
Initial interest in its sole approved treatment is solid, too. Despite a steep price tag of $2.2 million per patient, over 500 people have at least begun using its single marketed therapy, one that was only approved in late 2023. And the debt-light $5.5 billion company has over $2.4 billion worth of liquidity, while analysts consensus price target of $80.62 is 40% above the stock s current price.
Will AI create the world s first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »